222 related articles for article (PubMed ID: 35950920)
41. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.
Arpino G; Bardou VJ; Clark GM; Elledge RM
Breast Cancer Res; 2004; 6(3):R149-56. PubMed ID: 15084238
[TBL] [Abstract][Full Text] [Related]
42. Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapy.
Wong H; Lau S; Cheung P; Wong TT; Parker A; Yau T; Epstein RJ
BMC Cancer; 2014 Nov; 14():826. PubMed ID: 25385074
[TBL] [Abstract][Full Text] [Related]
43. Canonical Kaiso target genes define a functional signature that associates with breast cancer survival and the invasive lobular carcinoma histological type.
Sijnesael T; Richard F; Rätze MA; Koorman T; Bassey-Archibong B; Rohof C; Daniel J; Desmedt C; Derksen PW
J Pathol; 2023 Dec; 261(4):477-489. PubMed ID: 37737015
[TBL] [Abstract][Full Text] [Related]
44. Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial.
Metzger-Filho O; Procter M; de Azambuja E; Leyland-Jones B; Gelber RD; Dowsett M; Loi S; Saini KS; Cameron D; Untch M; Smith I; Gianni L; Baselga J; Jackisch C; Bell R; Sotiriou C; Viale G; Piccart-Gebhart M
J Clin Oncol; 2013 Jun; 31(16):1954-60. PubMed ID: 23589556
[TBL] [Abstract][Full Text] [Related]
45. Immune Infiltration in Invasive Lobular Breast Cancer.
Desmedt C; Salgado R; Fornili M; Pruneri G; Van den Eynden G; Zoppoli G; Rothé F; Buisseret L; Garaud S; Willard-Gallo K; Brown D; Bareche Y; Rouas G; Galant C; Bertucci F; Loi S; Viale G; Di Leo A; Green AR; Ellis IO; Rakha EA; Larsimont D; Biganzoli E; Sotiriou C
J Natl Cancer Inst; 2018 Jul; 110(7):768-776. PubMed ID: 29471435
[TBL] [Abstract][Full Text] [Related]
46. Comparative Long-term Study of a Large Series of Patients with Invasive Ductal Carcinoma and Invasive Lobular Carcinoma. Loco-Regional Recurrence, Metastasis, and Survival.
García-Fernández A; Lain JM; Chabrera C; García Font M; Fraile M; Barco I; Torras M; Reñe A; González S; González C; Piqueras M; Veloso E; Cirera L; Pessarrodona A; Giménez N
Breast J; 2015; 21(5):533-7. PubMed ID: 26190560
[TBL] [Abstract][Full Text] [Related]
47. Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population.
Wang T; Ma Y; Wang L; Liu H; Chen M; Niu R
Tumour Biol; 2015 Aug; 36(8):6113-24. PubMed ID: 25804795
[TBL] [Abstract][Full Text] [Related]
48. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas.
Delpech Y; Coutant C; Hsu L; Barranger E; Iwamoto T; Barcenas CH; Hortobagyi GN; Rouzier R; Esteva FJ; Pusztai L
Br J Cancer; 2013 Feb; 108(2):285-91. PubMed ID: 23299541
[TBL] [Abstract][Full Text] [Related]
49. Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma.
Gruel N; Lucchesi C; Raynal V; Rodrigues MJ; Pierron G; Goudefroye R; Cottu P; Reyal F; Sastre-Garau X; Fourquet A; Delattre O; Vincent-Salomon A
Eur J Cancer; 2010 Sep; 46(13):2399-407. PubMed ID: 20570624
[TBL] [Abstract][Full Text] [Related]
50. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes.
Rakha EA; El-Sayed ME; Powe DG; Green AR; Habashy H; Grainge MJ; Robertson JF; Blamey R; Gee J; Nicholson RI; Lee AH; Ellis IO
Eur J Cancer; 2008 Jan; 44(1):73-83. PubMed ID: 18035533
[TBL] [Abstract][Full Text] [Related]
51. Genetic predisposition to in situ and invasive lobular carcinoma of the breast.
Sawyer E; Roylance R; Petridis C; Brook MN; Nowinski S; Papouli E; Fletcher O; Pinder S; Hanby A; Kohut K; Gorman P; Caneppele M; Peto J; Dos Santos Silva I; Johnson N; Swann R; Dwek M; Perkins KA; Gillett C; Houlston R; Ross G; De Ieso P; Southey MC; Hopper JL; Provenzano E; Apicella C; Wesseling J; Cornelissen S; Keeman R; Fasching PA; Jud SM; Ekici AB; Beckmann MW; Kerin MJ; Marme F; Schneeweiss A; Sohn C; Burwinkel B; Guénel P; Truong T; Laurent-Puig P; Kerbrat P; Bojesen SE; Nordestgaard BG; Nielsen SF; Flyger H; Milne RL; Perez JI; Menéndez P; Benitez J; Brenner H; Dieffenbach AK; Arndt V; Stegmaier C; Meindl A; Lichtner P; Schmutzler RK; Lochmann M; Brauch H; Fischer HP; Ko YD; ; Nevanlinna H; Muranen TA; Aittomäki K; Blomqvist C; Bogdanova NV; Dörk T; Lindblom A; Margolin S; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Chenevix-Trench G; ; Lambrechts D; Weltens C; Van Limbergen E; Hatse S; Chang-Claude J; Rudolph A; Seibold P; Flesch-Janys D; Radice P; Peterlongo P; Bonanni B; Volorio S; Giles GG; Severi G; Baglietto L; McLean CA; Haiman CA; Henderson BE; Schumacher F; Le Marchand L; Simard J; Goldberg MS; Labrèche F; Dumont M; Kristensen V; Winqvist R; Pylkäs K; Jukkola-Vuorinen A; Kauppila S; Andrulis IL; Knight JA; Glendon G; Mulligan AM; Devillee P; Tollenaar RA; Seynaeve CM; Kriege M; Figueroa J; Chanock SJ; Sherman ME; Hooning MJ; Hollestelle A; van den Ouweland AM; van Deurzen CH; Li J; Czene K; Humphreys K; Cox A; Cross SS; Reed MW; Shah M; Jakubowska A; Lubinski J; Jaworska-Bieniek K; Durda K; Swerdlow A; Ashworth A; Orr N; Schoemaker M; Couch FJ; Hallberg E; González-Neira A; Pita G; Alonso MR; Tessier DC; Vincent D; Bacot F; Bolla MK; Wang Q; Dennis J; Michailidou K; Dunning AM; Hall P; Easton D; Pharoah P; Schmidt MK; Tomlinson I; Garcia-Closas M
PLoS Genet; 2014 Apr; 10(4):e1004285. PubMed ID: 24743323
[TBL] [Abstract][Full Text] [Related]
52. Tumor characteristics and patient outcomes are similar between invasive lobular and mixed invasive ductal/lobular breast cancers but differ from pure invasive ductal breast cancers.
Bharat A; Gao F; Margenthaler JA
Am J Surg; 2009 Oct; 198(4):516-9. PubMed ID: 19800459
[TBL] [Abstract][Full Text] [Related]
53. The role of histological subtype in hormone receptor positive metastatic breast cancer: similar survival but different therapeutic approaches.
Lobbezoo D; Truin W; Voogd A; Roumen R; Vreugdenhil G; Dercksen MW; van den Berkmortel F; Smilde T; van de Wouw A; van Kampen R; van Riel J; Peters N; Peer P; Tjan-Heijnen VC
Oncotarget; 2016 May; 7(20):29412-9. PubMed ID: 27121067
[TBL] [Abstract][Full Text] [Related]
54. Mixed invasive ductal lobular carcinoma is clinically and pathologically more similar to invasive lobular than ductal carcinoma.
Nasrazadani A; Li Y; Fang Y; Shah O; Atkinson JM; Lee JS; McAuliffe PF; Bhargava R; Tseng G; Lee AV; Lucas PC; Oesterreich S; Wolmark N
Br J Cancer; 2023 Apr; 128(6):1030-1039. PubMed ID: 36604587
[TBL] [Abstract][Full Text] [Related]
55. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.
Metzger Filho O; Giobbie-Hurder A; Mallon E; Gusterson B; Viale G; Winer EP; Thürlimann B; Gelber RD; Colleoni M; Ejlertsen B; Debled M; Price KN; Regan MM; Coates AS; Goldhirsch A
J Clin Oncol; 2015 Sep; 33(25):2772-9. PubMed ID: 26215945
[TBL] [Abstract][Full Text] [Related]
56. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.
Fu X; Jeselsohn R; Pereira R; Hollingsworth EF; Creighton CJ; Li F; Shea M; Nardone A; De Angelis C; Heiser LM; Anur P; Wang N; Grasso CS; Spellman PT; Griffith OL; Tsimelzon A; Gutierrez C; Huang S; Edwards DP; Trivedi MV; Rimawi MF; Lopez-Terrada D; Hilsenbeck SG; Gray JW; Brown M; Osborne CK; Schiff R
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):E6600-E6609. PubMed ID: 27791031
[TBL] [Abstract][Full Text] [Related]
57. Potential role of Fbxo22 in resistance to endocrine therapy in breast cancer with invasive lobular carcinoma.
Nakagawa S; Miyashita M; Maeda I; Goda A; Tada H; Amari M; Kojima Y; Tsugawa K; Ohi Y; Sagara Y; Sato M; Ebata A; Harada-Shoji N; Suzuki T; Nakanishi M; Ohta T; Ishida T
Breast Cancer Res Treat; 2024 Apr; 204(3):453-463. PubMed ID: 38180699
[TBL] [Abstract][Full Text] [Related]
58. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
59. Intratumoral estrogen production and actions in luminal A type invasive lobular and ductal carcinomas.
Takagi M; Miki Y; Miyashita M; Hata S; Yoda T; Hirakawa H; Sagara Y; Rai Y; Ohi Y; Tamaki K; Ishida T; Suzuki T; Ouchi N; Sasano H
Breast Cancer Res Treat; 2016 Feb; 156(1):45-55. PubMed ID: 26943913
[TBL] [Abstract][Full Text] [Related]
60. Long-Term Survival Differences Between T1-2 Invasive Lobular Breast Cancer and Corresponding Ductal Carcinoma After Breast-Conserving Surgery: A Propensity-Scored Matched Longitudinal Cohort Study.
Wang K; Zhu GQ; Shi Y; Li ZY; Zhang X; Li HY
Clin Breast Cancer; 2019 Feb; 19(1):e101-e115. PubMed ID: 30502219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
